These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16168122)

  • 1. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.
    Rehman A; Chahal MS; Tang X; Bruce JE; Pommier Y; Daoud SS
    Breast Cancer Res; 2005; 7(5):R765-74. PubMed ID: 16168122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.
    Lee K; Wang T; Paszczynski AJ; Daoud SS
    Biochem Biophys Res Commun; 2006 Oct; 349(3):1117-24. PubMed ID: 16970918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
    Liang Y; Besch-Williford C; Hyder SM
    Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
    Wang T; Lee K; Rehman A; Daoud SS
    Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
    Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P
    Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
    Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
    Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
    Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
    J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
    Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
    Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
    Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
    J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
    Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ
    Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
    Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
    Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
    Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
    Orue A; Chavez V; Strasberg-Rieber M; Rieber M
    BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
    Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C
    Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.
    Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
    Br J Haematol; 2004 Nov; 127(3):285-91. PubMed ID: 15491287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
    Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins.
    Rökaeus N; Klein G; Wiman KG; Szekely L; Mattsson K
    Oncogene; 2007 Feb; 26(7):982-92. PubMed ID: 16909106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
    Bykov VJ; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
    Nat Med; 2002 Mar; 8(3):282-8. PubMed ID: 11875500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
    Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
    Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.